New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT06334432
Summary
This study is testing a new drug called NUV-1511 in adults with advanced solid tumors that have stopped responding to standard treatments. The first part checks the drug's safety and finds the right dose, while the second part looks at how well it shrinks tumors in specific cancers like breast, prostate, pancreatic, and ovarian. Researchers will monitor patients closely for side effects and measure tumor changes using scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Fred Hutchinson
Seattle, Washington, 98109, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
Irving, Texas, 75038, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
START Mountain
Salt Lake City, Utah, 84124, United States
Conditions
Explore the condition pages connected to this study.